Figure 5

Efficacy of NV-01 in a model of inflammation induced pain. A) Average lameness scores are shown for each treatment group compared with the average lameness scores for the negative control group: The negative control was a single injection of phosphate buffered saline by intravenous infusion (IV, black triangles); Meloxicam (positive control) was given daily per os (PO) (grey squares); One 0.2 mg/kg dose of NV-01 was given by intravenous infusion (blue triangles); or one 0.2 mg/kg dose of NV-01 was given by subcutaneous injection (SC) (green circles). Points are the mean of eight animals per group. Error bars are the standard error of the mean. * p < 0.10; ** p < 0.05; *** p < 0.01 (Mann–Whitney test, one-tailed: test article compared to placebo). Arrows represent administration of the test article on the specified day. B) NV-01 serum concentration was determined by ELISA over a period of seven days in animals from the study given 0.2 mg/ml of NV-01 by intravenous infusion (blue triangles) or subcutaneous injection (green circles). Points are the mean NV-01 serum concentrations of three animals per group. Error bars are the standard deviation.